CK2B Induces CD8 + T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202411053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Shaochuan Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, CD8-Positive T-Lymphocytes, Casein Kinase II. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Tianjin Key Medical Discipline (Specialty) Construction Project, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Anti‐PD‐1 therapy has left an indelible mark in the field of non‐small‐cell lung cancer (NSCLC) treatment; however, its efficacy is limited in clinical practice owing to differences in the degree of effector T‐cell exhaustion. Casein kinase 2 (CK2) is a protein kinase that plays an important role in T‐cell immunity. In this study, it is aimed to explore the potential of targeting CK2 and its regulatory subunit CK2B to prevent or reverse T‐cell exhaustion, thereby enhancing the efficacy of anti‐PD‐1 therapy in NSCLC. In this study, it is found that CK2B expression is closely associated with T‐cell exhaustion as well as the efficacy of anti‐PD‐1 therapy based on scRNA‐seq and in vitro and in vivo experiments. Utilization of CK2 inhibitors or knockdown of CK2B expression can upregulate TBX21 expression through HDAC8‐mediated epigenetic reprogramming, restoring the effector function of CD8 + T cells and enhancing the efficacy of anti‐PD‐1 therapy in NSCLC. These findings underscore CK2B as a promising target for overcoming the exhaustion of effector CD8 + T cells, thereby enhancing the efficacy of anti‐PD‐1 and adoptive cell therapies in NSCLC. Moreover, CK2B expression serves as a novel predictor of immunotherapy efficacy for NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, 300060, China.
- Key Laboratory of Cancer Prevention and Therapy, Tianjin, 300060, China.
- Tianjin's Clinical Research Center for Cancer, Tianjin, 300060, China.
- Key Laboratory of Cancer Immunology and Biotherapy, Tianjin, 300060, China.
- Department of Immunology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, 300060, China.
- Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, 300060, China.
ORCID-Profile: Shaochuan Liu, Qian Sun
Förderung
- National Natural Science Foundation of China
- Tianjin Key Medical Discipline (Specialty) Construction Project
- China Postdoctoral Science Foundation
Zitieren
APA
Liu, S., Ma, S., Liu, G., Hou, L., Guan, Y., Liu, L., Meng, Y., Yu, W., Liu, T., Zhou, L., Yuan, Z., Pang, S., Zhang, S., Li, J., Ren, X., & Sun, Q. (2025). CK2B Induces CD8 + T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer. Advanced Science. https://doi.org/10.1002/advs.202411053
Vancouver
Liu S, Ma S, Liu G, Hou L, Guan Y, Liu L, et al. CK2B Induces CD8 + T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer. Advanced Science. 2025. doi:10.1002/advs.202411053
BibTeX
@article{Liu2025,
author = {Liu, Shaochuan and Ma, Shiya and Liu, Gen and Hou, Lingjie and Guan, Yong and Liu, Liang and Meng, Yuan and Yu, Wenwen and Liu, Ting and Zhou, Li and Yuan, Zhiyong and Pang, Shuju and Zhang, Siyuan and Li, Junyi and Ren, Xiubao and Sun, Qian},
title = {CK2B Induces CD8 + T‐Cell Exhaustion through HDAC8‐Mediated Epigenetic Reprogramming to Limit the Efficacy of Anti‐PD‐1 Therapy in Non‐Small‐Cell Lung Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202411053}
}
EUVIMED